Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung
Sponsors
Merck Sharp & Dohme LLC, Goethe University Frankfurt
Conditions
Advanced/Metastatic Gastroesophageal Adenocarcinomaintermediate and high-risk rectal cancer
Phase 3
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
Active, not recruitingCTIS2023-504834-23-00
Start: 2021-02-24Target: 231Updated: 2025-12-17
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients, A randomized phase III trial of the German Rectal Cancer Study Group
Active, not recruitingCTIS2024-511577-29-01
Start: 2020-03-13Target: 688Updated: 2026-01-26